IMR Press / EJGO / Volume 31 / Issue 3 / pii/1630985085761-1833055721

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Analysis of clinical and molecular associations of triple negative breast cancers in node-negative patients
Show Less
1 1st Department of Propedeutic Surgery, Hippokration Hospital, University of Athens
2 2nd Department of General Surgery, 3Breast Surgical Unsit, IASO General Clinic, Athens (Greece)
Eur. J. Gynaecol. Oncol. 2010, 31(3), 304–307;
Published: 10 June 2010
Abstract

Introduction: Therapeutic modalities in node-negative breast cancer patients remain a matter of controversy. Various prognostic factors have been proposed to help select those patients that would most likely benefit from adjuvant therapy. In view of this notion the triple negative phenotype (hormone receptors and HER2 negative tumors) has gained increasing attention. Aim: To evaluate the clinicopathologic characteristics of triple negative (TN) tumors in node-negative invasive breast carcinomas. Methods:We retrospectively analyzed the archival pathology tissues of 160 patients with node-negative invasive carcinomas, diagnosed and treated in two surgical departments in Greece from 1999 to 2006. Statistical analysis was used to examine the association between TN tumors and other clinicopathological factors. Results: Triple negative breast cancers correlated with higher histologic grade, mitotic activation index and Ki-67 expression (p < 0.05). Moreover TN tumors were correlated with negative staining for bcl-2 (p < 0.05). Conclusion: In node-negative breast cancer patients, triple negativity is associated with aggressive biologic behavior. Further studies are required to better understand the clinical implications of these findings.
Keywords
Triple negative breast cancer
Molecular profile
EGFR expression
Share
Back to top